Clinical Trial

NADream: Effects of Nicotinamide Adenine Dinucleotide Supplementation on Sleep Quality in Healthy Individuals

Study acronym: NADream
Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated September 15, 2025 (before its estimated May 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
The purpose of this study is to evalue the effects of nicotinamide adenine dinucleotide (NAD) supplementation (nicotinamide riboside (NR) form) on sleep in healthy adults compared to a placebo. NAD is important for brain health and energy balance and a proposed explanation for its effect on sleep is that NAD supplementation restores the neurophysiological capacity of the brain to 'rest' during sleep. If this is the case, we expect the administration to result in improvements in sleep quality (and most likely sleep quantity) compared to placebo. Participants will receive either NAD supplementation or a placebo and their sleep will be measured to detect any differences between the two groups.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-05-12.
Trial Details
NCT Number NCT06971224
Lead Sponsor Haukeland University Hospital
Collaborators: University of Bergen
Conditions Sleep
Enrollment 16 participants
Start Date 2025-10-13
Primary Completion 2026-05-01 (estimated)
Study Completion 2026-06-01 (estimated)
Updated on ClinicalTrials.gov 2025-09-15